Internal Medicine, Hematology & Oncology · New York, NY
NPI
1376719104
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
1 Gustave L Levy Pl, Box 1079
New York, NY, 10029
Phone (212) 241-1948
Groups this clinician bills Medicare through
Medicare paid, 2024
$55K
657 services
Medicare patients, 2024
197
Average age 75
Drug cost, 2024
$3.1M
511 prescriptions
Company payments, 2025
$67K
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by John Mascarenhas was code 99214 (office e&m - established), 476 times for 146 patients. In total John Mascarenhas billed 657 services in 14 codes, and Medicare paid $55K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-07-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 476 | 146 | $77.43 | $37K |
| 99233 Hospital E&M - Subsequent | Facility | 90 | 21 | $99.33 | $8,940 |
| 99205 Office E&M - New | Facility | 32 | 32 | $140.26 | $4,488 |
| 99204 Office E&M - New | Facility | 12 | 12 | $111.51 | $1,338 |
By year: 2022 $48K for 545 services; 2023 $56K for 603 services; 2024 $55K for 657 services.
Medicare prescription drug claims, 2024
In 2024, the drug John Mascarenhas prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 78 prescriptions and refills. In total John Mascarenhas wrote 511 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 78 | 80 | 19 | $1.4M |
| Allopurinol Generic | 55 | 87 | Under 11 | $468 |
| Acyclovir Generic | 46 | 61 | 11 | $672 |
| Hydroxyurea Generic | 30 | 50 | 17 | $494 |
| Posaconazole Generic | 30 | 30 | Under 11 | $18K |
| Levofloxacin Generic | 27 | 30 | Under 11 | $367 |
| Vonjo Pacritinib Citrate | 25 | 25 | Under 11 | $594K |
| Xarelto Rivaroxaban | 22 | 34 | Under 11 | $19K |
| Ondansetron Odt Ondansetron | 12 | 14 | Under 11 | $142 |
Brand drugs: 218 claims; generic drugs: 293 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid John Mascarenhas $67K ($65K in general payments such as food, travel and fees and $2,002 for research) from 15 companies. The largest payer was Incyte Corporation with $21K.
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation INCY | 13 | $21K |
| Sumitomo Pharma America, Inc. 4506.T | 4 | $14K |
| Geron Corporation GERN | 7 | $8,298 |
| Karyopharm Therapeutics Inc. KPTI | 5 | $7,246 |
| Sobi, Inc SOBI.ST | 4 | $5,785 |
| GlaxoSmithKline, LLC. GSK | 6 | $3,849 |
| Sanofi US Services Inc. SNY | 1 | $2,580 |
| Merck Sharp & Dohme LLC MRK | 2 | $1,923 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $1,531 |
| Novartis Pharmaceuticals Corporation NVS | 7 | $607 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.